PlainRecalls
FDA Drug Moderate Class II Ongoing

Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Rx Only, 100 Capsules, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-562-01.

Reported: December 11, 2024 Initiated: November 1, 2024 #D-0095-2025

Product Description

Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Rx Only, 100 Capsules, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-562-01.

Reason for Recall

cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

Details

Units Affected
25584 bottles
Distribution
Nationwide in the USA
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Rx Only, 100 Capsules, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-562-01.. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 25584 bottles.
Why was this product recalled?
cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on December 11, 2024. Severity: Moderate. Recall number: D-0095-2025.